Keywords
Checkpoint
PascalFrancis
Racine
Checkpoint
PascalFrancis
Exploration
Accueil
Racine
Racine

Movement Disorders (revue) - Checkpoint (PascalFrancis)

Index « Keywords » - entrée « Reuptake inhibitor »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Rett syndrome < Reuptake inhibitor < Reverse transcription  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 20.
Ident.Authors (with country if any)Title
000061 (2012) M. Konno ; T. Haseqawa ; T. BabaSelective Serotonin Reuptake Inhibitors Emerge as the Therapeutic Agent for Synucleinopathies
000361 (2011) Klaus Seppi ; Daniel Weintraub ; Miguel Coelho ; Santiago Perez-Lloret ; Susan H. Fox ; Regina Katzenschlager ; Eva-Maria Hametner ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz ; Cristina SampaioThe Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease
001495 (2007) Robert A. Hauser [États-Unis] ; Laurence Salin [France] ; Nolwenn Juhel [France] ; Victor L. Konyago [États-Unis]Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (Tesofensine) in early parkinson's disease
001F79 (2004) Matthew J. Hansard [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sharon C. Cheetham [Royaume-Uni] ; Peter Jenner [Royaume-Uni]The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates
002166 (2004) William Bara-Jimenez [États-Unis] ; Tzvetelina Dimitrova [États-Unis] ; Abdulah Sherzai [États-Unis] ; Antonella Favit [États-Unis] ; M. M. Mouradian [États-Unis] ; Thomas N. Chase [États-Unis]Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease
002574 (2002) Treatment of depression in idiopathic Parkinson's disease
002582 (2002) Ronald K. B. Pearce [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jorgen Scheel-Krüger [Danemark] ; Peter Jenner [Royaume-Uni]The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets
002850 (2002) David J. Burn [Royaume-Uni]Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease
002A63 (2001) José A. Dominguez-Moran [Espagne] ; Juan M. Callejo [Espagne] ; Luis C. Fernandez-Ruiz [Espagne] ; Juan C. Martinez-Castrillo [Espagne]Acute paroxysmal dystonia induced by fluoxetine
002A91 (2000) Silvana Tesei [Italie] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Anna Zecchinelli [Italie] ; Claudio B. Mariani [Italie] ; Gianni Pezzoli [Italie]Tolerability of paroxetine in Parkinson's disease : A prospective study
002D25 (1999) D. Mathen [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; K. P. Bhatia [Royaume-Uni]SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia
002E36 (1999) I. H. Richard [États-Unis] ; A. Maughn [États-Unis] ; R. Kurlan [États-Unis]Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series
003054 (1998) I. M. Bronner [Pays-Bas] ; J. A. L. Vanneste [Pays-Bas]Complex movement disorder associated with fluvoxamine
003089 (1998) R. Kurlan [États-Unis]Acute parkinsonism induced by the combination of a serotonin reuptake inhibitor and a neuroleptic in adults with Tourette's syndrome
003144 (1997) M. Poyurovsky [Israël] ; M. Schneidman [Israël] ; A. Weizman [Israël]Successful treatment of fluoxetine-induced dystonia with low-dose mianserin
003157 (1997) R. A. Hauser [États-Unis] ; T. A. Zesiewicz [États-Unis]Sertraline for the treatment of depression in Parkinson's disease
003285 (1997) F. Ghika-Schmid [Suisse] ; J. Ghika [Suisse] ; P. Vuadens [Suisse] ; J. Bogousslavsky [Suisse] ; F. Regli [Suisse] ; P. A. Despland [Suisse]Acute reversible myoclonic encephalopathy associated with fluoxetine therapy
003295 (1997) P. G. Como [États-Unis] ; A. J. Rubin [États-Unis] ; C. F. O'Brien [États-Unis] ; K. Lawler [États-Unis] ; C. Hickey [États-Unis] ; A. E. Rubin [États-Unis] ; R. Henderson [États-Unis] ; M. P. Mcdermott [États-Unis] ; T. Mcdermott [États-Unis] ; K. Steinberg [États-Unis] ; I. Shoulson [États-Unis]A controlled trial of fluoxetine in nondepressed patients with Huntington's disease
003387 (1996) K. J. Bharucha [États-Unis] ; K. D. Sethi [États-Unis]Complex movement disorders induced by fluoxetine
003577 (1994) E. C. Lauterbach [États-Unis]Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick's disease

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/KwdEn.i -k "Reuptake inhibitor" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/KwdEn.i  \
                -Sk "Reuptake inhibitor" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Reuptake inhibitor
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024